Assignee
RXI PHARMACEUTICALS CORP
US·6 granted patents·8 pending applications·217 citations·filing 2007–2016
Top patents by PatentIndex Score
14 records- 0198US9938530B2RNA interference in skin indicationsRXI PHARMACEUTICALS CORP·Filed 2016·Granted Apr 10, 2018·25 cites·19 claims
- 0298US9303259B2RNA interference in skin indicationsRXI PHARMACEUTICALS CORP·Filed 2013·Granted Apr 5, 2016·46 cites·12 claims
- 0398US9175289B2Reduced size self-delivering RNAi compoundsRXI PHARMACEUTICALS CORP·Filed 2014·Granted Nov 3, 2015·80 cites·17 claims
- 0497US10167471B2Inhibition of PCSK9 through RNAIRXI PHARMACEUTICALS CORP·Filed 2016·Granted Jan 1, 2019·20 cites·11 claims
- 0596US10184124B2RNA interference in ocular indicationsRXI PHARMACEUTICALS CORP·Filed 2015·Granted Jan 22, 2019·23 cites·14 claims
- 0696US9963702B2RNA interference in dermal and fibrotic indicationsRXI PHARMACEUTICALS CORP·Filed 2016·Granted May 8, 2018·23 cites·20 claims
- 0756US2015105448A1Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identificationRXI PHARMACEUTICALS CORP·Filed 2014·Application pending·0 cites
- 0855US2011251258A1Rnai constructs and uses thereofRXI PHARMACEUTICALS CORP·Filed 2009·Application pending·0 cites
- 0953US2009131360A1Tripartite RNAi constructsRXI PHARMACEUTICALS CORP·Filed 2008·Application pending·0 cites
- 1048US2010069620A1Novel compositions of chemically modified small interfering rnaRXI PHARMACEUTICALS CORP·Filed 2007·Application pending·0 cites
- 1146US2016304875A1Methods for treatment of wound healing utilizing chemically modified oligonucleotidesRXI PHARMACEUTICALS CORP·Filed 2014·Application pending·0 cites
- 1243US2019029974A1Methods for treating skin disorders and conditions utilizing haptensRXI PHARMACEUTICALS CORP·Filed 2016·Application pending·0 cites
- 1339US2018263925A1Methods for the treatment of alopecia areata utilizing gene modulation approachesRXI PHARMACEUTICALS CORP·Filed 2015·Application pending·0 cites
- 1433US2017051290A1Methods for treatment of disorders in the front of the eye utilizing nucleic acid moleculesRXI PHARMACEUTICALS CORP·Filed 2015·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →